Twenty-one patients with goiters-four diffuse and 17 nodular-were treated with I-triiodothyronine and I-thyroxine in doses to tolerance. The four diffuse goiters were barely palpable at the end of the treatment. The average dose of I-triiodothyronine required was 100 mcg. per day. The average dose of I-thyroxine was 0.3 mg. per day. Of the 17 multinodular goiters, 11 showed at least a 50 per cent reduction in size. The average dose of I-triiodothyronine used was 125 mcg. In six cases the gland did not change in size; in three of the six the lesion was diagnosed, at operation, as microfollicular and macrofollicular colloid goiter. Hypermetabolic symptoms may occur when doses of 100 mcg. or more of I-triiodothyronine are used. Results indicated that suppressive therapy with thyroid hormone to tolerance is effective in diffuse goiters. It is only partially effective in the treatment of multinodular goiters. In the cases in which operation was done, no change in the basic histological goiter structure was observed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1575601 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Predicting brain tumour growth patterns using a novel MRI-based tumour spread map: application to radiotherapy planning.
Med Phys
January 2025
Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, Canada.
Background: The treatment of glioblastomas (GBM) with radiation therapy is extremely challenging due to their invasive nature and high recurrence rate within normal brain tissue.
Purpose: In this work, we present a new metric called the tumour spread (TS) map, which utilizes diffusion tensor imaging (DTI) to predict the probable direction of tumour cells spread along fiber tracts. We hypothesized that the TS map could serve as a predictive tool for identifying patterns of likely recurrence in patients with GBM and, therefore, be used to modify the delivery of radiation treatment to pre-emptively target regions at high risk of tumour spread.
Dose measurements with the Pille-ISS thermoluminescent dosimeter system during extravehicular activities (2004-2022).
Life Sci Space Res (Amst)
February 2025
Institute of Biomedical Problems of the Russian Academy of Sciences, 76A Khoroshevskoye shosse, 123007, Moscow, Russian Federation.
One of the most problematic goals for radiation safety during spaceflight is an assessment of additional doses received by astronauts during extravehicular activity (EVA). The Pille-ISS thermoluminescent dosimeter developed by the predecessor of the Hungarian Research Network (HUN-REN) Centre for Energy Research (Budapest, Hungary) is designed for the routine dose measurements not only inside the spacecraft compartments, but also for personal dosimetric control for EVA. During almost two decades of the International Space Station (ISS) operation, the unique set of 131 EVA doses were recorded in different conditions, such as: solar activity, ISS trajectory along the South Atlantic Anomaly (SAA), and shielding conditions provided by two kinds of spacesuits: the Extravehicular Mobility Unit (EMU) and Orlan.
View Article and Find Full Text PDFDose verification of 2 targets simultaneously for single-isocenter stereotactic radiation therapy and radiosurgery plans.
Med Dosim
January 2025
Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Most of conventional 2-dimensional (2D) methods verify dose of multiple targets separately one-by-one for Single-isocenter Multiple-target (SIMT) brain plans, which are inefficient and sub-optimal. This study presented a practical method to verify the dose of 2 targets simultaneously for improved efficiency and accuracy. Fifteen Stereotactic Radiation Therapy (SRT) and sixteen Stereotactic Radiosurgery (SRS) plans were used for this study.
View Article and Find Full Text PDFSafety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
Lancet Neurol
February 2025
Janssen Research & Development, a Johnson & Johnson Company, Titusville, NJ, USA.
Background: Given burdensome side-effects and long latency for efficacy with conventional agents, there is a continued need for generalised myasthenia gravis treatments that are safe and provide consistently sustained, long-term disease control. Nipocalimab, a neonatal Fc receptor blocker, was associated with dose-dependent reductions in total IgG and anti-acetylcholine receptor (AChR) antibodies and clinically meaningful improvements in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale in patients with generalised myasthenia gravis in a phase 2 study. We aimed to assess the safety and efficacy of nipocalimab in a phase 3 study.
View Article and Find Full Text PDFThe Application of Olive-Derived Polyphenols on Exercise-Induced Inflammation: A Scoping Review.
Nutrients
January 2025
Cambridge Centre for Sport and Exercise Sciences (CCSES), Faculty of Science and Engineering, Anglia Ruskin University, Cambridge CB1 1PT, UK.
Background/objectives: There is current scientific interest pertaining to the therapeutic effects of olive-derived polyphenols (ODPs), in particular their associated anti-inflammatory properties, following the wealth of research surrounding the physiological impact of the Mediterranean Diet (MD). Despite this association, the majority of the current literature investigates ODPs in conjunction with metabolic diseases. There is limited research focusing on ODPs and acute inflammation following exercise, regardless of the knowledge surrounding the elevated inflammatory response during this time.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!